Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 173 results for "sarabjit kour nangra"

Weak rupee: analysts see minimal margin boost for IT exporters

Despite the depreciation in the rupee, which tends to help IT exporters, the impact on their operating margins in the third quarter of the 2015 fiscal year will be minimal. Earlier this month, the rupee hit an 8-month low of 62.22 against the US ... Hindu Business Line, 10 hours ago

1 images for "sarabjit kour nangra"

Times of India, 1 week ago

Dr Reddy's unit receives USFDA observations on possible lapses

The US Food and Drug Administration (USFDA) has found what it calls nine inspectional observations at Unit VI of Dr Reddy's Laboratories Srikakulam plant. The apex regulator has through Form 483 sought explanation on the nine observations that are ...
 Financial Express1 day ago We maintain neutral stance on Dr Reddy`s: Angel Broking  MyIris1 day ago Dr Reddy's unit receives US FDA observations on possible lapses  Financial Express17 hours ago

US FDA discovers lapses at DRL's Srikakulam plant

US health regulator Food and Drug Administration (FDA) has procedural deviations at Dr Reddy's Laboratories manufacturing plant at Srikakulam Hyderabad: US health regulator Food and Drug Administration (FDA) has procedural deviations at Dr ...
 Deccan Chronicle1 day ago DRL Visakhapatnam Plant Gets FDA Fiat on Suspected Lapses  New Indian Express1 day ago Dr Reddy's plant gets USFDA fiat on suspected lapses  Business Standard India1 day ago Dr Reddy's Plant Gets FDA Fiat On Suspected Lapses  The Freepress Journal1 day ago

Ranbaxy's Nexium pay-for-delay case to go on trial

The pay-for-delay case over heartburn pill Nexium, that Ranbaxy is caught in, is set to go to trial as the judge for Massachusetts Federal court said the case must go before the jury. Buyers of the drug had filed a lawsuit alleging that patent owner ...
 Financial Chronicle2 days ago Angel Broking remains neutral on Ranbaxy  MyIris2 days ago Lupin joins hands with Merck Serono for emerging markets  Financial Chronicle2 months ago Angel Broking remains neutral on Lupin  MyIris2 months ago
Times of India

Tech Mahindra acquires US company for $240m

BENGALURU: India's fifth-largest IT services company Tech Mahindra said it will acquire Virginia, US-based Lightbridge Communications Corporation (LCC) for $240 million (over Rs 1,400 crore), making it the largest overseas acquisition it has ever ...
 Times of India1 week ago TechM buys US network services firm for $240m  The Financial Chronicle1 week ago Tech Mahindra : acquires US company for $240m  4 Traders6 days ago

Techm Buys LCC For Rs 1486 Cr In Biggest Indian IT Deal This Year

— By | Nov 21, 2014 01:09 am With An Annual Revenue Of About $430 Mn, Lightbridge Communications Will Help The Country's Fifth-Largest Software Services Firm Strengthen Its Presence In The Fast-Growing Telecom And Enterprises Network Market New ...
 The Freepress Journal6 days ago Tech Mahindra to buy LCC for $240 mn in largest Indian IT deal this year  Samaylive6 days ago Tech Mahindra buys US company for 240 million  Hindustan Times6 days ago Tech Mahindra buys LCC for $240 million in largest Indian IT deal this year  DNA India1 week ago

Ranbaxy Laboratories : sues FDA for revoking approvals

Mumbai : Ranbaxy Laboratories , the company in waiting to be merged with Sun Pharma, has taken a legal recourse against the US drug regulator for revoking the tentative approvals granted for launching the generic versions of AstraZeneca's heartburn ...
 4 Traders1 week ago Ranbaxy files suit against USFDA for revoking approved drugs  DNA India1 week ago Ranbaxy sues FDA for revoking approvals [DNA : Daily News & Analysis (India)]  Pharmacy Choice1 week ago Double blow to Ranbaxy  Calcutta Telegraph3 weeks ago

US court overturns Ranbaxy bid to block launch of rival generic drugs

In a setback, the US court has denied a request by drug-maker Ranbaxy Laboratories to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche€s antiviral Valcyte. Ranbaxy had sought the restraining order against ...
 MyIris1 week ago

Ranbaxy sues USFDA for revoking drug approvals

For long at the receiving end, Ranbaxy Laboratories Ltd has chosen to go on the offensive against the United States Food and Drug Administration (USFDA), suing the US regulator for revoking tentative approvals given to it six years ago to launch ...
 Hindu Business Line1 week ago Ranbaxy sues USFDA for revoking approvals for 2 drugs; stk down  Economic Times1 week ago
Business Today India

Cipla shares down 2.4 % post Q2 results

closed down by 2.45 per cent, wiping out Rs 1,228.13 crore from its market valuation, as the company's September quarter results were "below" market expectations. Cipla fell by 2.93 per cent to Rs 605.85 in day trade before closing at Rs 608.85, ...
 Business Standard India1 week ago Cipla shares fall as second quarter numbers disappoint  Business Today India1 week ago Cipla shares fall almost 3% post Q2 results  Hindu Business Line1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less